|
Facet Biotech Names Ted Llana, Ph.D. Senior Vice President, Commercial and Corporate Development
(Marketwire Via Acquire Media NewsEdge) REDWOOD CITY, CA, January 12 / MARKET WIRE/ --
Facet Biotech Corporation (NASDAQ: FACT)
today announced the appointment of Ted Llana, Ph.D. as Senior Vice
President, Commercial and Corporate Development, of the company. Dr. Llana
will be responsible for leading the company's corporate development,
business development and new product planning activities.
"Ted is a key addition to our senior leadership team, as he brings a
tremendous amount of strategic business experience and solid scientific
skills to the organization," said Faheem Hasnain, president and chief
executive officer of Facet Biotech. "We are looking forward to his
contributions in helping to shape Facet into a promising new biotech
company."
From September 2001 to November 2008, Dr. Llana held various positions of
increasing responsibility at Biogen Idec Inc., including most recently as
Vice President, Oncology/Rheumatology Strategic Business Unit. In his most
recent role at Biogen Idec, he defined and executed the strategy to grow
and progress Biogen Idec's oncology and rheumatology pipelines and managed
Biogen Idec's Rituxan? collaboration with Genentech, Inc. Prior to
working in the oncology business unit, Dr. Llana headed up corporate
strategy at Biogen Idec and led global marketing at Biogen. Dr. Llana's
prior business experience includes serving as a partner at Documedics, Inc.
and as a Vice President at Covance, Inc. where he provided strategic
consulting on product commercialization and marketing in the
pharmaceutical, biotechnology and medical device industries. Dr. Llana
began his career as a Biologist at the National Cancer Institute. He
received his Ph.D. in Cellular Immunology from Cornell University and his
MBA from Georgetown.
About Facet Biotech
Facet Biotech is a biotechnology company dedicated to advancing its
pipeline of four clinical-stage products and leveraging its research and
development capabilities to identify and develop new drugs. Facet Biotech
Corporation launched in December 2008 as a spin-off from PDL BioPharma,
Inc.
NOTE: Facet Biotech and the Facet Biotech logo are considered trademarks of
Facet Biotech Corporation. Rituxan is a registered trademark of Biogen Idec
Inc.
Contact:
Jean Suzuki
Investor Relations
(650) 454-2648jean.suzuki@facetbiotech.com
Copyright ? 2009 Marketwire
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
INDUSTRIES
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, September 1-3, 2009. Los Angeles, CA.
